Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes

Endocrinology & Metabolism Clinics of North America · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles